Class III PMA Track Readiness Toolkit
PMA application structure guide, IDE-to-PMA transition plan, pivotal study design, SSED template, advisory panel preparation, and post-approval study management — for Class III medical device programs.
What You Get
PMA Application Structure Guide (21 CFR Part 814)
Complete guide to structuring a Premarket Approval application per 21 CFR 814.20. Covers all required PMA sections: device description, indications for use, contraindications, warnings, precautions, device description, alternative practices, marketing history, summary of studies, conclusions, bibliography, manufacturing information, and the proposed labeling. Maps each section to FDA review expectations and common deficiency patterns that delay PMA approval.
IDE to PMA Transition Planning Template
Strategic planning template for transitioning from IDE clinical study to PMA submission. Covers pivotal study completion milestones, statistical analysis plan finalization, clinical study report preparation timeline, pre-PMA meeting strategy, manufacturing scale-up coordination, and the 180-day PMA review period resource planning. Includes the pre-submission strategy that reduces PMA deficiency letters.
Pivotal Clinical Study Design Template for PMA
Clinical study design template for PMA pivotal trials. Covers study design rationale (RCT, non-inferiority, superiority), primary and secondary endpoints, sample size justification, statistical analysis plan, interim analysis strategy, adaptive design considerations, and the study design elements FDA evaluates most critically during PMA review. Structured for Q-Sub meeting discussion.
PMA Summary of Safety and Effectiveness Data (SSED) Template
Complete SSED template per 21 CFR 814.20(b)(8). Covers device description, indications, contraindications, warnings, clinical studies (description, statistical analysis, results), non-clinical tests (performance testing, biocompatibility, sterilization, software, EMC), benefit-risk determination, and the conclusions that must demonstrate reasonable assurance of safety and effectiveness.
FDA Advisory Panel Preparation Toolkit
Preparation framework for FDA advisory panel meetings that occur during PMA review for high-risk devices. Covers panel meeting structure, sponsor presentation format (typically 30-45 minutes), the types of questions panelists ask, benefit-risk communication strategies, and the pre-panel meeting preparation activities that maximize the probability of a favorable panel recommendation.
PMA Condition of Approval and Post-Approval Study Management Template
Template for managing PMA conditions of approval and required post-approval studies. Covers condition tracking, annual PMA report preparation (21 CFR 814.84), post-approval study protocol management, FDA progress report format, and the PMA supplement strategy for device modifications after approval. Includes the 30-day notice and 180-day PMA supplement decision framework.
FAQ
What is the FDA PMA review timeline?
FDA has a 180-day statutory review period for PMAs after filing acceptance. In practice, most PMAs go through multiple deficiency letter rounds and take 2-3 years from initial submission to approval for complex Class III devices.
Does every Class III device require a PMA?
Most Class III devices require PMA approval. Exceptions include Class III devices cleared via 510k before the class III determination was made (preamendments devices with post-1976 marketing history) and De Novo-classified devices. The PMA requirement applies to new Class III devices and Class III devices whose preamendments status was not established.
What format are the documents?
All documents are editable Word and Excel templates.
Ready to get started?
For informational purposes only. Not legal or regulatory advice. Legal